Description
Product Usage Information
For optimal ChIP results, use 10 μL of antibody and 10 μg of chromatin (approximately 4 × 10 6 cells) per IP. This antibody has been validated using SimpleChIP ® Enzymatic Chromatin IP Kits.
Western Blotting: 1:1000
Simple Western™: 1:50 - 1:250
Immunoprecipitation: 1:100
Chromatin IP: 1:50
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody.
Protocol
Available protocols: Western Blotting, Immunoprecipitation, Chromatin IP
Specificity / Sensitivity
ARID3A (F1G2E) Rabbit Monoclonal Antibody recognizes endogenous levels of total ARID3A protein. This antibody detects a 180 kDa protein of unknown identity in some cell lines.
Species Reactivity: Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro109 of human ARID3A protein.
Background
AT-rich interactive domain-containing protein 3A (ARID3A), also known as B-cell regulator of IgH transcription (Bright), is a multifaceted DNA-binding protein and a member of the extensive ARID family of proteins, many of which are recognized for their roles in chromatin remodeling and epigenetic regulation. ARID3A contains an ARID domain, a conserved DNA-binding motif that allows for recognition and binding to AT-rich DNA sequences (1). This protein typically functions as a dimer (and can form heterodimers with ARID3B) for its DNA-binding activity (2,3). Beyond binding to DNA, ARID3A is also involved in chromatin remodeling and can influence chromatin accessibility. For instance, in the context of immunoglobulin (Ig) gene regulation, it has been shown to increase the accessibility of the Ig heavy chain enhancer (4). ARID3A has been shown to play an essential role in embryonic development and hematopoiesis as ARID3A knockout mice exhibit early embryonic lethality due to severe defects in both early hematopoietic stem cell populations and erythropoiesis (5,6). ARID3A has also been linked to autoimmune diseases, particularly systemic lupus erythematosus (SLE), where increased ARID3A expression in B cells and other hematopoietic cell types correlates with increased disease severity (7). Moreover, ARID3A misregulation is also implicated in various cancers (8-10). Importantly, various post-translational modifications such as phosphorylation, ubiquitination, and SUMOylation on ARID3A have been identified, and SUMOylation of this protein specifically underscores a key mechanism for targeting and modulating its transcriptional activity (11).
Alternate Names
ARI3A; ARID domain-containing 3A; ARID domain-containing protein 3A; ARID3A; AT rich interactive domain 3A (BRIGHT- like) protein; AT rich interactive domain 3A (BRIGHT-like); AT-rich interaction domain 3A; AT-rich interactive domain-containing protein 3A; B-cell regulator of IgH transcription; Bright; dead ringer-like 1; Dead ringer-like protein 1; DRIL1; DRIL3; DRX; E2F-binding protein 1; E2FBP1
